Denosumab 60 mg Q6M vs Placebo: Number of Participants With a Hip Fracture
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00666 | 0.00455 | 0.00975 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.011 | 0.00818 | 0.0148 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00435 | -0.00868 | -0.000164 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.605 | 0.373 | 0.983 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.603 | 0.37 | 0.983 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Denosumab 60 mg Q6M than on Placebo | 230 | 115 | 6,090 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Denosumab 60 mg Q6M | Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years. | 26 | 3,902 | OG001 | ClinicalTrials.gov |
| Group 2 | Placebo | Placebo administered subcutaneously once every 6 months for 3 years. | 43 | 3,906 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With a Hip Fracture | ClinicalTrials.gov |
| Description | Hip fractures are a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter. | ClinicalTrials.gov |
| Time frame | 36 months | ClinicalTrials.gov |
| Population | Full analysis set | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis | ClinicalTrials.gov |
| NCT number | NCT00089791 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Osteoporosis | ClinicalTrials.gov |
| Interventions | placebo, Denosumab | ClinicalTrials.gov |
| Lead sponsor | Amgen | ClinicalTrials.gov |
| Results first posted | 2014-01-10 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00089791?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.